The Biotinylated Anti-GPRC5D Antibody (HDLA052) is a valuable tool for researchers studying GPRC5D, a cell surface receptor protein involved in various cellular activities. This antibody, produced in-house using a high-quality biotinylation process, is specifically designed for use in immunohistochemistry and immunofluorescence applications.GPRC5D, also known as G protein-coupled receptor family C group 5 member D, is a potential therapeutic target in cancer research due to its role in cell proliferation, survival, and migration. By utilizing this antibody, researchers can detect and visualize GPRC5D expression in tissue samples, helping to further understand its functions and potential implications in cancer biology.
With its high specificity and sensitivity, the Biotinylated Anti-GPRC5D Antibody (HDLA052) is a valuable tool for researchers investigating the role of GPRC5D in cancer progression and therapeutic development. Its application in immunohistochemistry and immunofluorescence techniques makes it an essential component in studies focused on understanding the molecular mechanisms underlying cancer biology.
SKU:
HDLA052
Size:
100 µg
Clonality:
Monoclonal
Clone:
DM90
Synonyms:
GPRC5D
Applications:
ELISA, Flow Cyt
Recommended Dilution:
ELISA 1:5000-10000; Flow Cyt 1:100
Host Species:
Rabbit
Isotype:
Rabbit IgG
Reactivity:
Human
Purification Method:
Purified from cell culture supernatant by affinity chromatography
Formulation:
Powder
Buffer:
1XPBS
Storage:
Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing).Lyophilized antibodies are shipped at ambient temperature.
Usage:
Research use only
Background:
The protein encoded by this gene is a member of the G protein-coupled receptor family. Recent studies demonstrate that GPRC5D is expressed on malignant bone marrow plasma cells, whereas normal tissue expression is limited to the hair follicle. It may represent a potential target for effector-cell–mediated therapy to treat plasma-cell disorders like MM.
